A stabilized GHRH analog with the rare distinction of FDA approval (as Egrifta) — studied for visceral adipose tissue reduction and the metabolic consequences of growth hormone deficiency states.
Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence stabilized with a trans-3-hexenoic acid modification that improves its stability and half-life compared to natural GHRH. Developed by Theratechnologies, Tesamorelin achieved FDA approval in 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — a metabolic condition where antiretroviral drugs cause characteristic fat redistribution (loss of limb fat, accumulation of visceral abdominal fat).
This FDA approval gave Tesamorelin an unusually strong clinical data set compared to most peptides in this library. Phase III clinical trials documented its effects on visceral adipose tissue (VAT) quantitatively using imaging technology. Beyond its approved indication, Tesamorelin has been studied in broader body composition research and as a tool for investigating the GH axis in aging and growth hormone deficiency states.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. Elevated GH then promotes IGF-1 production in the liver. The net metabolic effect on visceral fat involves IGF-1's ability to promote lipolysis (fat breakdown) in adipocytes, particularly visceral fat cells which appear more responsive to GH/IGF-1 signaling than subcutaneous fat.
The trans-3-hexenoic acid modification protects the peptide from rapid enzymatic degradation by DPP-4 (dipeptidyl peptidase 4), extending its biological half-life and allowing twice-daily dosing in the clinical trial context.
Think of visceral fat as a warehouse that grew out of control while the building manager (growth hormone) was on extended leave. Tesamorelin is like calling the manager back to work — not giving someone else the keys (that would be direct GH injection), but stimulating the original manager to resume their normal duties. The pituitary makes more GH, IGF-1 rises in the liver, and the visceral fat warehouses start getting cleared out because the natural management system is running again.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Tesamorelin (Egrifta) has one of the best-characterized clinical dosing profiles of any GHRH analog — phase III trials and FDA approval provide large-cohort human data from two randomized controlled trials (ENCORE-1 and ENCORE-2).
Key References: Falutz J et al. (2010). Tesamorelin HIV lipodystrophy ENCORE-1. NEJM. · Falutz J et al. (2014). ENCORE-2. AIDS. · Stanley TL et al. (2014). Tesamorelin in non-HIV adults. J Clin Endocrinol Metab.
Tesamorelin (Egrifta) is one of only a handful of peptides in the entire research peptide space that has achieved FDA approval. Most peptides are stuck in preclinical or early clinical stages for decades. The HIV lipodystrophy indication gave it a clear, measurable endpoint (visceral fat by CT scan) that made clinical trial success possible.
In Phase III trials, Tesamorelin produced approximately 15–18% reduction in visceral adipose tissue area as measured by CT imaging over 26 weeks — a quantitative finding that's unusually precise for body composition research.
The DPP-4 protection mechanism in Tesamorelin (trans-3-hexenoic acid modification) is similar to how GLP-1 analog drugs (like semaglutide) achieve stability — protecting the N-terminal peptide bond from the DPP-4 enzyme that degrades natural GLP-1 and GHRH within minutes.
Every batch of Tesamorelin with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.